By Colin Kellaher
Eyenovia on Friday said it is exploring its strategic options following the failure of a late-stage study of its proposed treatment for nearsightedness in children.
The ophthalmic technology company said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform as a potential treatment for pediatric progressive myopia after an independent review found that the trial wasn't meeting its primary three-year efficacy endpoint.
Eyenovia said it will now reduce expenses and consider a variety of options to maximize value for its shareholders, including a business combination, reverse merger or asset sales.
Trading in shares of the New York company, which closed Thursday at 34 cents, was halted premarket on Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 15, 2024 07:21 ET (12:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。